Skip to main content
. 2023 Jan 6;14:108. doi: 10.1038/s41467-022-35732-1

Fig. 7. Chronic anti-inflammatory treatment normalizes muscle inflammation, rescues muscle atrophy, ameliorates physical performance, and improves exercise-induced IL6 response.

Fig. 7

a NFκB target gene expression in quadriceps muscles of PBS- or salicylate-treated (200 mg/kg, 28 days) LoxP (n = 4 mice) and SkM-Mfn1KO male mice (n = 5 mice). b Representative images of hematoxylin/eosin staining of cross-sectional sections of gastrocnemius muscles (Scale bar, 100 µm) and quantification of the CSA from PBS- or salicylate-treated mice (n = 3 mice; 4 areas per mice; 30 fibers per area). c CK activity in plasma samples in LoxP (n = 12 mice) and SkM-Mfn1KO PBS- or salicylate-treated male mice (n = 12 mice). d Fgf21 mRNA levels in quadriceps muscles of LoxP (n = 5 mice) and SkM-Mfn1KO PBS- or salicylate-treated male mice (n = 7 mice). e Plasma FGF21 levels in LoxP (n = 7 mice) and SkM-Mfn1KO PBS- or salicylate-treated male mice (n = 9 mice). f Distance run on the treadmill test and the difference in the distance run between day 2 and day 1 in LoxP (n = 7 mice) and SkM-Mfn1KO PBS- or salicylate-treated male mice (n = 7 mice). g Plasma IL6 levels of LoxP and SkM-Mfn1KO PBS- or salicylate-treated male mice at resting conditions or at different time-points after the treadmill test (n = 8 mice). a–g Two-way ANOVA test and post hoc t tests. Data are expressed as mean ± SEM. *p vs. LoxP + PBS < 0.05, #p vs. SkM-Mfn1KO + PBS < 0.05. a–g Source data is provided in the Source Data File.